Research Triangle Park, NC (Vocus) April 30, 2010
Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that Nimish Shah has joined the public affairs department as vice president, federal government relations.
Shah will serve as a member of the federal affairs lobbying and policy team that represents Talecris to the legislative and executive branches of government in Washington, D.C. He will collaborate with members of the public affairs team to lead Talecris’ political action committee and to educate internal and external audiences on key policy initiatives that affect Talecris’ business.
Shah brings a diverse set of skills and experience in the fields of public policy, law and business, including strategic oversight and implementation of government affairs outreach programs, regulatory and reimbursement policy development, and patient advocacy and alliance partnerships.
Before joining Talecris, Shah served as senior director and head of Takeda Pharmaceuticals’ D.C. office, where he developed and led the company’s lobbying, policy and patient advocacy functions. Prior to his position at Takeda, Shah served as director of public policy and manager of public policy and federal government affairs at Roche Pharmaceuticals. Shah spent the first twelve years of his career practicing law in Philadelphia and Washington, D.C., respectively.
Nimish earned his Bachelor of Arts degree in International Relations from Rutgers University in New Brunswick, N.J. He earned his Juris Doctor from the Rutgers School of Law and an Executive Master of Business degree from the Rutgers School of Business. He also participated in the International Law Program at Regent’s College in London, England.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: http://www.talecris.com.
Talecris Corporate Communications
Becky Levine, 919-316-6590